Background-Clinical trials of cardiac resynchronization therapy (CRT) have enrolled a select group of patients, with few patients in subgroups such as right bundle-branch block (RBBB). Analysis of population-based outcomes provides a method to identify real-world predictors of CRT outcomes. Methods and Results-Medicare Implantable Cardioverter-Defibrillator Registry (2005 to 2006) data were merged with patient outcomes data. Cox proportional-hazards models assessed death and death/heart failure hospitalization outcomes in patients with CRT and an implantable cardioverter-defibrillator (CRT-D). The 14 946 registry patients with CRT-D (median follow-up, 40 months) had 1-year, 3-year, and overall mortality rates of 12%, 32%, and 37%, respectively. New York Heart Association class IV heart failure status ( 
C linical trials have established that cardiac resynchronization therapy (CRT), either alone or in combination with an implantable cardioverter-defibrillator (ICD) (CRT-D), improves survival and heart failure (HF) symptoms in appropriately selected patients. [1] [2] [3] [4] Although clinical trials have provided the basis for the current use of CRT, these clinical trials are selective in the patients they enroll and in the treatment offered, so the treatment provided in clinical trials differs meaningfully from what patients typically receive in practice. 5 In addition, subgroup analysis is limited in these trials by the small number of patients with select characteristics. As a result, uncertainty remains about the clinical determinants of CRT effectiveness in clinical practice in typical target populations such as older patients with Medicare coverage.
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Factors likely to influence clinical outcomes after CRT include surface ECG findings such as bundle-branch block (BBB) morphology, coexisting ischemic heart disease, age, and the presence of arrhythmias such as atrial fibrillation. Relative to BBB morphology, current guidelines specify that patients should have a QRS duration (QRSd) Ն120 ms but make no additional specifications in this regard. 6 Even so, it is reasonable to expect different outcomes with right BBB (RBBB) and left BBB (LBBB) because RBBB is associated with less left ventricular mechanical dyssynchrony than LBBB. 7, 8 Clinical trials have not definitively addressed this issue because subgroup analysis from clinical trials of CRT based on BBB morphology is difficult as a result of the limited number of patients with RBBB enrolled in these trials. Recent nonrandomized series with limited numbers of patients with RBBB have reached conflicting conclusions on this issue. 9 -11 We used the data from the Medicare ICD Registry to characterize prognosis after CRT-D and to assess the relationship between clinical factors measured at the time of implantation and outcomes after CRT-D in Ϸ15 000
Medicare patients. In particular, we tested the hypothesis that patients with RBBB have significantly worse outcomes after CRT-D implantation than those with LBBB. Linkage of the ICD implantation registry data with Medicare beneficiary enrollment and use data files maintained by the Research Data Distribution Center was conducted for the purpose of this research by CMS. All data files produced for this research were stored in encrypted format and maintained on secured-access computers. Analyses of all data were approved by the CMS Privacy Board.
Methods

Characteristics of the ICD Registry, Medicare Claims, and Medicare Eligibility Records
Patients included all had a QRSd of at least 120 ms and a left ventricular ejection fraction (LVEF) Յ0.35. Patients with New York Heart Association (NYHA) HF class less than III or IV at the time of implantation were included because the NYHA classification provides a limited assessment 12 and class scores significantly fluctuate over time in patients. In addition, CRT has been shown to result in beneficial remodeling in selected class I and II patients on the basis of the Multicenter Automatic Defibrillator Implantation Trial-CRT (MADIT-CRT). 13 
Statistical Analysis
Two-sided t tests were used to compare unadjusted means for continuous variables between the RBBB and LBBB groups, and Fisher exact tests were used to compare unadjusted proportions for categorical variables between these groups. Kaplan-Meier curves with death alone and death plus HF hospitalizations as the outcomes of interest were calculated to assess unadjusted comparisons of time to event for HF patients with RBBB and LBBB having received CRT-D. The log-rank test statistic was used to determine the statistical significance of unadjusted differences in time to event. A Cox proportional hazards model was used to assess the statistical significance of BBB morphology as a predictor of survival, adjusted for the concurrent effects of differences in patient demographics, clinical history, clinical characteristics, device information, and the other previously described covariates. The effect of BBB morphology (LBBB, RBBB, and intraventricular conduction delay [IVCD]) on survival was represented as a hazard ratio (HR) and 95% confidence interval (CI), with the effects referent to patients with LBBB. The same methodology was used to calculate adjusted HRs for the events of interest (death and the combined outcome of death or hospitalization) censored at 1 year and separately for events censored at 3 years using the identical set of covariates. Wald 2 tests were used to assess the significance of individual covariates. Events were assessed at both 1 and 3 years to determine whether there were any meaningful differences in the effects of the covariates at these Figure 1 . Kaplan-Meier curves for BBB morphology. KaplanMeier plots are shown for freedom from death alone (A) and freedom from death or heart failure hospitalization (B) in patients with CRT-D. Patients with RBBB had higher rates of both outcomes than those with LBBB, and those with a nonspecific IVCD had an intermediate prognosis. follow-up points and to facilitate comparison with published clinical trial data. In the larger ICD registry cohort (nϭ24 486) with an LVEF Յ0.35 and QRSd Ն120 ms receiving either CRT-D (nϭ14 946) or standard ICDs (nϭ9540), the interaction between BBB morphology and whether the patient received CRT-D or a standard ICD (BBBϫCRT) was also tested in similar Cox proportional-hazards models with death or death/HF hospitalization as the outcomes. The Wald 2 test was used to assess the significance of the interaction, and specific HRs were determined for CRT based on BBB morphology. This study was reviewed and approved as exempt human subjects research by the Institutional Review Board of the University of Virginia.
Results
The frequency and distributional characteristics measured for the study population are listed in Table 1 . Among 14 946 patients who received CRT-D and met standard QRS and LVEF criteria for CRT implantation, 10 356 (69%) had an LBBB, 1638 (11%) had an RBBB, and 2952 (20%) had a nonspecific IVCD. Most patients were on appropriate medical therapy with angiotensinconverting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) and ␤-blockers.
Patient mortality and hospitalization outcomes at 30 days and at 1, 2, and 3 years of follow-up are presented in Table 2 . 
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During the available follow-up period, 5557 (37.2%) died, 5088 (34.0%) had an HF hospitalization, and 7821 (52.3%) experienced the composite outcome of death or HF hospitalization. The median available follow-up period was 40 months. Of the 37.2% of patients who died during the entire follow-up period, 12.6% died during the first year after CRT-D, after which Ϸ10% died during each of the second and third years of follow-up, resulting in a 3-year mortality rate of 31.8%. Approximately half of the patients (48.2%) either died or were hospitalized for HF by the end of the third year of follow-up, with many of these reaching this composite end point during the first year after CRT-D implantation. Death alone and the composite end point were more common in patients with RBBB than in those with LBBB, and those with a nonspecific IVCD had intermediate outcomes. As shown in Figure 1A , 45.8% of patients with RBBB compared with 35.0% of those with LBBB died during follow-up. As shown in Figure 1B , death or HF hospitalization occurred in 60.2% of patients with RBBB compared with 50.0% of patients with LBBB during follow-up. The survival curves continue to separate during the 4 years, and the log-rank test statistic was highly significant (PϽ0.0001) for both models. Unadjusted rates of death and the composite outcome at 1 and 3 years differed significantly by bundlebranch morphology, cardiomyopathy type, and QRSd, as shown in Table 3 . This table also shows poor outcomes for patients with baseline NYHA class IV HF, with a 21.6% mortality rate during the first year and 44.3% dying over 3 years.
Results for the Cox proportional-hazards model assessing adjusted predictors of death are presented in Table 4 . This includes adjustment for all covariates, including QRSd, which had the distribution shown in Figure 2 . After NYHA class IV HF and age Ն80 years, RBBB (1- 4 or for subgroup analysis 14 ) had a decreased hazard compared with those with QRSd of 120 to 149 ms, with an HR of 0.77 (95% CI, 0.70 to 0.84) at 1 year and 0.86 (95% CI, 0.81 to 0.91) at 3 years. Diabetes mellitus and atrial fibrillation were associated with an increased hazard, whereas ACE inhibitors/ARBs and ␤-blockers were associated with a decreased hazard. These covariates were also important predictors in the Cox proportional-hazards model for the composite end point of death or HF hospitalization, as presented in Table 5 . Figure 3 provides a summary of absolute death rates based on BBB morphology and cardiomyopathy type. The combination of RBBB and ischemic cardiomyopathy was associated with nearly double the unadjusted mortality rate at 1, 2, and 3 years compared with patients with LBBB and nonischemic cardiomyopathy (3-year mortality comparison: 41.9% versus 22.4%; PϽ0.0001), whereas RBBB with nonischemic cardiomyopathy or LBBB with ischemic cardiomyopathy resulted in intermediate death rates. These effects were consistent at all follow-up intervals.
For comparison, Figure 4 shows both unadjusted ( Figure  4A ) and adjusted ( Figure 4B ) HRs from the Cox proportional-hazards model for death. As shown in Figure 3 , RBBB/ischemic cardiomyopathy was associated with approximately twice the hazard (HR, 1.99; 95% CI, 1.75 to 2.26) of LBBB/nonischemic cardiomyopathy for both the unadjusted and adjusted analyses.
The adjusted hazards in Table 6 with patients parsed into groups based on BBB morphology and QRSd show a significant decrease in the hazard for either outcome in LBBB when the QRSd is at least 150 ms. In contrast, QRSd did not have any significant effects on outcomes with RBBB present.
For the 24 496 registry patients (includes the original 14 946 patients) with a wide QRS and confirmed LVEF of Յ0.35 who received either CRT-D or a standard ICD, similar Cox proportional-hazards models with the addition of interaction terms for BBB morphology and CRT implantation showed significant interaction terms for both models (PϽ0.05), as shown in Tables I and II in 
Discussion
This large population-based study demonstrates that even with optimal medical therapy (nearly 80% of patients receiving ␤-blockers and ACE inhibitors or ARBs) and state-ofthe-art CRT-D device therapy, approximately one third of patients died during the first 3 years of follow-up after CRT-D, and about half either died or were hospitalized for HF. Among all patients receiving CRT-D, BBB morphology was among the most powerful predictors of outcome, even after adjustment for QRS width 15, 16 and other covariates. This study also demonstrated a significant influence on prognosis after CRT-D for other clinical variables, including NYHA class IV HF, age Ն80 years, ischemic cardiomyopathy (consistent with the deleterious effects of increased scar burden 17, 18 and ischemia 19 in CRT), diabetes mellitus, and atrial fibrillation (consistent with known effects of atrial arrhythmias in patients with CRT 20 ). Medications such as ACE inhibitors and ␤-blockers were associated with favorable outcomes, whereas diuretic use was associated with a worse prognosis, consistent with other studies of HF. 21 Although clinical trials of CRT [1] [2] [3] [4] are the foundation for current recommendations for CRT implantation, patients in clinical trials are highly selected, and treatment may differ from clinical practice. 5, 23 As a result, less is known about factors influencing CRT outcomes in clinical practice, particularly in patients with Medicare, who make up a large proportion of patients referred for CRT-D. The ICD Registry presents an excellent data repository for answering this question, and the merge with Medicare outcomes data provided a 40-month median follow-up (versus 16 months in the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure [COMPANION] ). 1 Other studies of mortality after ICDs in Medicare patients used the Medicare data set only and had limited information available about predictors were similar to those in registry patients. COMPANION showed a 17.6% CRT-D death rate during the median 16 months of follow-up, but the death rate in registry patients over 40 months was 37.2%. This finding highlights the fact that although CRT-D improves symptoms and survival for HF patients, HF is a progressive disease, and real-world mortality rates over 3 to 4 years are high and difficult to infer from clinical trials with shorter follow-up periods.
This death rate also reflects the fact that registry patients were Ϸ7 years older than patients in the COMPANION trial (73 versus 66 years). The present study also extends the observations of the MADIT-2 27 and other investigators 28 relative to age and ICD outcomes in patients with CRT-D in that patients Ͼ80 years of age had a significantly higher death rate in our cohort. Even so, the risk factors discussed in the present analysis were still strong predictors even after adjustment for age. With regard to gender, although ICDs are underused in women, 29 female patients did no worse than their male counterparts in this cohort.
Both RBBB and shorter QRSd had significantly higher short-term and long-term adjusted hazards for death among all patients with CRT-D. We note that these differences among CRT-D patients do not address differences in treatment efficacy, and in the absence of a control group for comparison, potential systematic differences in baseline disease related to treatment allocation cannot be separated from potential differences in response to therapy. Furthermore, it is not possible to determine whether an increased hazard indicates decreased benefit relative to the reference or harm. With these caveats, it is important to note that HF with RBBB is nevertheless different from HF with LBBB (less circumferential mechanical dyssynchrony, 8, 30 normal activation of the left ventricle in the absence of other disease, 7 and possible association with right ventricular dysfunction). In addition, pump failure was the most common cause of death in COMPANION, 31 and mortality rates after CRT-D may reflect different effects of CRT on pump function in different HF states. Of note, CRT-D device parameters may also not be optimized properly in routine practice for patients with RBBB.
The secondary analysis in patients with both CRT-D and standard ICDs, all with QRSd Ͼ120 ms and LVEF Յ0.35, was consistent with a CRT-specific influence of RBBB on outcomes. Because this analysis is limited by the fact that we were unable to control for additional factors that may have determined why certain patients received CRT-D and others received standard ICDs, we have based our primary analysis on the 14 946 patients who actually received CRT-D. Nevertheless, the consistency between the primary and secondary analyses is reassuring.
Limitations
The ICD Registry contained a reasonably complete characterization of the patients included; however, some potentially important characteristics were unavailable. For example, B-type natriuretic peptide and creatinine were not available; however, end-stage renal disease was rare (0.03%) in the study population. Characterization of right ventricular function may have an effect on CRT outcomes, but this information was not available. Although the existing registry data have inherent limitations, the registry provides the most clinically detailed record available for the broad population of older Americans who have received these devices. Death dates and HF hospitalizations are accurately reported in the Medicare database; however, because the primary ICD-9-CM code was used to determine whether a patient was hospitalized for HF, it was not possible to adjudicate further whether these admissions were truly for acute decompensated HF. Even so, the major findings of this study were related to death, and the COMPANION trial has shown that the majority of deaths in patients with CRT-D are cardiovascular. 31 
Conclusions
We have shown that Medicare patients, who are frequently referred for ICDs and CRT-D, had a persistent 10% to 12% annual mortality rate over Ͼ3 years of follow-up after CRT-D and that RBBB, ischemic cardiomyopathy, NYHA class IV HF, and age Ն80 years were the most powerful covariates predicting poor early and late outcomes after CRT-D. These data offer a realistic picture of HF as a progressive disease and show that outcomes vary significantly on the basis of BBB morphology and other covariates. In light of the increased complexity, procedure time, and follow-up requirements associated with CRT-D relative to standard ICD implantation, these factors influencing realworld outcomes after CRT-D should be considered when referring patients for CRT-D in clinical practice. 
